argenx SE (ARGX)
374.67
+5.92
(+1.61%)
USD |
NASDAQ |
Apr 23, 16:00
377.12
+2.45
(+0.65%)
After-Hours: 07:21
argenx Profit Margin (Quarterly): -24.38% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -24.38% |
| September 30, 2023 | -22.03% |
| June 30, 2023 | -34.88% |
| March 31, 2023 | -13.17% |
| December 31, 2022 | -22.17% |
| September 30, 2022 | -170.3% |
| June 30, 2022 | -277.6% |
| March 31, 2022 | -970.4% |
| December 31, 2021 | -913.9% |
| September 30, 2021 | -27.26K% |
| June 30, 2021 | 33.18% |
| March 31, 2021 | -25.57% |
| December 31, 2019 | -491.4% |
| September 30, 2019 | -329.8% |
| June 30, 2019 | -688.0% |
| March 31, 2019 | 18.51% |
| December 31, 2018 | -2.38K% |
| September 30, 2018 | -782.6% |
| June 30, 2018 | -10.43% |
| March 31, 2018 | -317.0% |
| Date | Value |
|---|---|
| December 31, 2017 | -139.1% |
| September 30, 2017 | -129.5% |
| June 30, 2017 | -2.09% |
| March 31, 2017 | -126.3% |
| December 31, 2016 | -227.9% |
| September 30, 2016 | -107.5% |
| June 30, 2016 | -127.4% |
| March 31, 2016 | -134.0% |
| December 31, 2015 | -286.1% |
| September 30, 2015 | -134.9% |
| June 30, 2015 | -269.1% |
| March 31, 2015 | -246.2% |
| December 31, 2014 | -256.2% |
| September 30, 2014 | -86.88% |
| June 30, 2014 | -1.19K% |
| March 31, 2014 | -546.0% |
| December 31, 2013 | -223.1% |
| September 30, 2013 | -6.14% |
| June 30, 2013 | -746.2% |
| March 31, 2013 | -414.4% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-27.26K%
Minimum
Sep 2021
33.18%
Maximum
Jun 2021
-2.08K%
Average
-170.3%
Median
Sep 2022
Profit Margin (Quarterly) Benchmarks
| TC BioPharm (Holdings) PLC | -- |
| Trinity Biotech PLC | -45.79% |
| Adaptimmune Therapeutics PLC | -20.74K% |
| Biodexa Pharmaceuticals Plc | -- |
| Merus NV | -672.9% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -9.66% |
| Return on Assets | -8.14% |
| Return on Invested Capital | -9.06% |
| Gross Profit Margin (Quarterly) | 90.30% |
| Operating Margin (Quarterly) | -33.63% |
| Return on Net Operating Assets | -30.35% |